Updated:
Nextbio Capital Management
Nextbio Capital Management invests in breakthrough medicine using next-gen technologies from a network of offices in North America and Europe.
Nextbio Capital Management
Nextbio Capital Management operates from a network of offices in fourteen cities across North America and Europe, including Bentonville, Boston, New York, London, and Paris. The firm's footprint suggests a decentralized approach, potentially linking scientific hubs with capital sources. Its founding year, principals, and wealth origin remain undisclosed in primary sources. The firm states it invests in breakthrough medicine through the application of next-generation technologies. Its strategy centers on biotechnology. The intersection of AI/ML and digital health tools appears central to its investment thesis. Confirmed portfolio positions, specific deal structures, and co-investor relationships are not publicly documented. Team size, total deployment figures, and discrete fund vehicles have not been disclosed. The multi-city office network, spanning Montreal, Hamburg, and Menlo Park, indicates an operational model that may embed personnel within innovation clusters without a centralized hub-and-spoke structure. Recent operational events could not be verified. Nextbio Capital Management's architecture — a flat network of offices without an obvious central gravity — distinguishes it from traditional single-location or flagship-headquartered life sciences investors. The lack of disclosed leadership, fund structures, or track record makes it impossible to assess whether the firm operates as a traditional venture capital partnership, a family office vehicle, or a project-finance platform.
General information
Firm type
Asset Manager
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Bentonville
Corporate office
Bentonville, AR, United States
Additional offices
Boston · New York · Greenwich · Austin · San Francisco · London · Montreal · Hamburg · Stamford · Paris · Amsterdam · Manhattan Beach · Menlo Park
Sector focus
Frequently asked questions
What is Nextbio Capital Management's investment strategy?
According to its website, the firm invests in breakthrough medicine through the application of next-generation technologies. This implies a focus on biotechnology companies leveraging advances in areas like artificial intelligence, machine learning, and digital health to improve drug discovery and development. Specific investment stages and financial instruments are not publicly detailed.
Where does Nextbio Capital Management operate?
The firm lists offices in fourteen cities: Bentonville, Boston, New York, Greenwich, Austin, San Francisco, London, Montreal, Hamburg, Stamford, Paris, Amsterdam, Manhattan Beach, and Menlo Park. This extensive geographic footprint spans major life sciences and technology hubs in both North America and Europe, suggesting a distributed team or investment presence without a single dominant headquarters.
Who are the principals leading Nextbio Capital Management?
The firm has not publicly named its founders, managing partners, or investment committee members on its primary website as of the latest review. The absence of disclosed leadership is a significant information gap for due diligence and represents an opaque governance structure relative to most institutional-grade life sciences investors.
What is the size of Nextbio Capital Management's assets under management?
Nextbio Capital Management does not publicly disclose its assets under management or total capital deployed. Without disclosed fund sizes, regulatory filings, or named investment leads, the firm's financial scale cannot be independently verified. The AUM remains undisclosed.
How is Nextbio Capital Management structured — is it a venture capital firm or a family office?
The firm's legal and operational structure is not publicly defined. Its wide office network, lack of named partners, and straightforward strategy statement do not clearly map to either a traditional venture capital firm or a single-family office. The structural ambiguity makes it difficult to classify the firm or understand its capital sources and governance.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on registered investment advisers?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: